Innowacje w walce z Ebolą: Rozwój szczepionek przeciwko wirusowi Ebola w XXI wieku
Keywords:
Ebola, EBOV, szczepionkiSynopsis
Należący do rodziny Filoviridae wirus Ebola (EBOV) stanowi czynnik etiologiczny groźnej gorączki krwotocznej Ebola (EVD). EVD charakteryzuje się wysoką śmiertelnością, a jej przypadki rejestrowane są niemal co roku, szczególnie w rejonach Afryki podatnych na występowanie ognisk epidemicznych. Pomimo wcześniejszych, licznych prób opanowania epidemii EVD, dopiero w ostatnich latach nastąpiło przełomowe odkrycie skutecznych i bezpiecznych szczepionek przeciw EBOV. Obecnie, wśród dostępnych na świecie preparatów wyróżnia się: Ervebo®, Zabdeno/Mvabea®, Ad5-EBOV® oraz GamEvac-Combi®. Pierwsze dwie szczepionki spośród wymienionych dostępne są na terenie Unii Europejskiej. Kolejne, obiecujące preparaty znajdują się aktualnie na etapie badań klinicznych. Należy jednak pamiętać, że szczepienia nie zastępują odpowiedniej higieny rąk, stosowania środków ochrony osobistej i segregacji odpadów medycznych, dlatego warto wdrożyć wszystkie z wymienionych rodzajów profilaktyki.
Chapters
-
Innowacje w walce z Ebolą: Rozwój szczepionek przeciwko wirusowi Ebola w XXI wieku
References
Baseler L, Chertow DS, Johnson KM, Feldmann H, Morens DM. The pathogenesis of Ebola virus disease. Annual Review of Pathology Mechanisms of Disease. 2016;12(1):387-418. doi:10.1146/annurev-pathol-052016-100506
Łuczkiewicz M, Flaga MJ. Gorączka krwotoczna Ebola. Immunologiczne i molekularne mechanizmy patogenezy, diagnostyka, eksperymentalne metody leczenia i uodparniania. Post Mikrobiol. 2007; 46(3): 189-202.
Janowska M, Polz-Dacewicz M, Prystupa A. Wirus Ebola – przeciwnik stale nieodkryty. Med Og Nauk Zdr. 2012; 18(4): 379-382
World Health Organization: WHO. Ebola virus disease. https://www.who.int/health-topics/ebola#tab=tab_1. Published June 18, 2019.
World Health Organization: WHO, World Health Organization: WHO. Ebola virus disease. https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease. Published April 20, 2023.
Gut W, Pancer K. Selected aspects of filoviruses in the view of Ebola virus disease epidemic. Przegl Epidemiol. 2015;69(1):15-130.
Languon S, Quaye O. Impacts of the Filoviridae family. Current Opinion in Pharmacology. 2021;60:268-274. doi:10.1016/j.coph.2021.07.016
Jacob ST, Crozier I, Fischer WA, et al. Ebola virus disease. Nature Reviews Disease Primers. 2020;6(1). doi:10.1038/s41572-020-0147-3
Feldmann H, Geisbert TW. Ebola haemorrhagic fever. The Lancet. 2010;377(9768):849-862. doi:10.1016/s0140-6736(10)60667-8
Liu CH, Hu YT, Wong SH, Lin LT. Therapeutic Strategies against Ebola Virus Infection. Viruses. 2022;14(3):579. doi:10.3390/v14030579
Rewar S, Mirdha D. Transmission of Ebola virus disease: An Overview. Annals of Global Health. 2015;80(6):444. doi:10.1016/j.aogh.2015.02.005
Kadanali A. An overview of Ebola virus disease. Northern Clinics of Istanbul. January 2016. doi:10.14744/nci.2015.97269
Tkaczuk K, Pogłód R, Grabarczyk P. Wirus EBOLA jako potencjalne wyzwanie dla krwiodawstwa, krwiolecznictwa i zdrowia publicznego. Journal of Transfusion Medicine. 149-165. 10.5603/jtm.56053.
Malvy D, McElroy AK, De Clerck H, Günther S, Van Griensven J. Ebola virus disease. The Lancet. 2019;393(10174):936-948. doi:10.1016/s0140-6736(18)33132-5
Ebola virus disease in West Africa — the first 9 months of the epidemic and forward projections. New England Journal of Medicine. 2014;371(16):1481-1495. doi:10.1056/nejmoa1411100
World Health Organization: WHO, Ebola response roadmap situation report. https://iris.who.int/bitstream/handle/10665/144498/roadmapsitrep_26Nov2014_eng.pdf?sequence=1. Published November 12, 2014.
World Health Organization: WHO, Ebola Situation Report – 28 January 2015. https://web.archive.org/web/20150131111021/http://apps.who.int/ebola/en/ebola-situation-report/situation-reports/ebola-situation-report-28-january-2015.
Ohimain EI, Silas-Olu D. The 2013–2016 Ebola virus disease outbreak in West Africa. Current Opinion in Pharmacology. 2021;60:360-365. doi:10.1016/j.coph.2021.08.002
Garske T, Cori A, Ariyarajah A, et al. Heterogeneities in the case fatality ratio in the West African Ebola outbreak 2013–2016. Philosophical Transactions of the Royal Society B Biological Sciences. 2017;372(1721):20160308. doi:10.1098/rstb.2016.0308
Outbreak history. Ebola. https://www.cdc.gov/ebola/outbreaks/?CDC_AAref_Val=https://www.cdc.gov/vhf/ebola/history/chronology.html. Published May 6, 2024.
Letafati A, Ardekani OS, Karami H, Soleimani M. Ebola virus disease: A narrative review. Microbial Pathogenesis. 2023;181:106213. doi:10.1016/j.micpath.2023.106213
World Health Organization: WHO, Sudan virus disease - Uganda. https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON556. Published February 21, 2025.
Ayoubi LWE, Mahmoud O, Zakhour J, Kanj SS. Recent advances in the treatment of Ebola disease: A brief overview. PLoS Pathogens. 2024;20(3):e1012038. doi:10.1371/journal.ppat.1012038
Rayaprolu V, Fulton BO, Rafique A, et al. Structure of the Inmazeb cocktail and resistance to Ebola virus escape. Cell Host & Microbe. 2023;31(2):260-272.e7. doi:10.1016/j.chom.2023.01.002
EU/3/18/2027 - orphan designation for treatment of Ebola virus disease | European Medicines Agency (EMA). European Medicines Agency (EMA). https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2027.
Ebola Disease Basics. Ebola. https://www.cdc.gov/ebola/about/index.html?CDC_AAref_Val=https://www.cdc.gov/vhf/ebola/treatment/index.html. Published April 23, 2024.
Kuehn R, Ryan H, Okwaraeke KC, et al. Vaccines for preventing Ebola virus disease. Cochrane Library. 2024;2024(11). doi:10.1002/14651858.cd015828
Malik S, Kishore S, Nag S, et al. Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges. Vaccines. 2023;11(2):268. doi:10.3390/vaccines11020268
Sharma AR, Lee YH, Nath S, Lee SS. Recent developments and strategies of Ebola virus vaccines. Current Opinion in Pharmacology. 2021;60:46-53. doi:10.1016/j.coph.2021.06.008
Wolf J, Jannat R, Dubey S, et al. Development of pandemic vaccines: ERVEBO case study. Vaccines. 2021;9(3):190. doi:10.3390/vaccines9030190
Charakterystyka produktu leczniczego. https://www.ema.europa.eu/pl/documents/product-information/ervebo-epar-product-information_pl.pdf
https://www.ema.europa.eu/pl/documents/overview/ervebo-epar-medicine-overview_pl.pdf
Ervebo: Package insert / prescribing information. Drugs.com. https://www.drugs.com/pro/ervebo.
Heppner DG, Kemp TL, Martin BK, et al. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. The Lancet Infectious Diseases. 2017;17(8):854-866. doi:10.1016/s1473-3099(17)30313-4
Zabdeno | WHO - Prequalification of medical products (IVDs, medicines, vaccines and immunization devices, vector control). https://extranet.who.int/prequal/vaccines/p/zabdeno.
Charakterystyka produktu leczniczego. https://www.ema.europa.eu/pl/documents/product-information/zabdeno-epar-product-information_pl.pdf
Charakterystyka produktu leczniczego. https://www.ema.europa.eu/pl/documents/product-information/mvabea-epar-product-information_pl.pdf
Zhu FC, Hou LH, Li JX, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet. 2015;385(9984):2272-2279. doi:10.1016/s0140-6736(15)60553-0
Zhang Z, Yang W, Chen Z, et al. A causal multiomics study discriminates the early immune features of Ad5-vectored Ebola vaccine recipients. The Innovation. 2024;5(3):100603. doi:10.1016/j.xinn.2024.100603
Li Y, Wang L, Zhu T, et al. Establishing China’s national standard for the recombinant adenovirus Type 5 Vector–Based Ebola vaccine (AD5-EBOV) virus TITER. Human Gene Therapy Clinical Development. 2018;29(4):226-232. doi:10.1089/humc.2018.129
Wu L, Zhang Z, Gao H, et al. Open-label phase I clinical trial of Ad5-EBOV in Africans in China. Human Vaccines & Immunotherapeutics. 2017;13(9):2078-2085. doi:10.1080/21645515.2017.1342021
World Health Organization: WHO, Overview of the current research, development and use, of vaccines against ebola. https://terrance.who.int/mediacentre/data/sage/SAGE_Docs_Ppt_Oct2019/7_session_ebola/Oct2019_Session7_R_DBlueprint_vaccines_against_ebola.pdf
Logunov DY, Dolzhikova IV, Boiro MY, et al. Safety and immunogenicity of GamEvac-Combi, a heterologous rVSV- and rAd5-vectored Ebola vaccine: a randomized controlled multicenter clinical trial in the Republic of Guinea and Russia. Frontiers in Immunology. 2025;16. doi:10.3389/fimmu.2025.1487039
Woolsey C, Geisbert TW. Current state of Ebola virus vaccines: A snapshot. PLoS Pathogens. 2021;17(12):e1010078. doi:10.1371/journal.ppat.1010078
Tomori O, Kolawole MO. Ebola virus disease: current vaccine solutions. Current Opinion in Immunology. 2021;71:27-33. doi:10.1016/j.coi.2021.03.008
Dolzhikova IV, Zubkova OV, Tukhvatulin AI, et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia. Human Vaccines & Immunotherapeutics. 2017;13(3):613-620. doi:10.1080/21645515.2016.1238535
Meyer M, Garron T, Lubaki NM, et al. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. Journal of Clinical Investigation. 2015;125(8):3241-3255. doi:10.1172/jci81532
Published
August 6, 2025
Copyright (c) 2025 Magdalena Trólka, Mateusz Faryniarz, Jakub Warecki
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
